Week in Review: Beijing's BeiGene Raises $185 Million for Clinical Trial Program
November 26, 2016 at 14:06 PM EST
BeiGene, a Beijing novel oncology biopharma, completed a $200 million secondary offering last week, up from its initial target of $150 million.
